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Abstract Bromodomains, an extensive family of evolutionarily
conserved protein modules originally found in proteins associated
with chromatin and in nearly all nuclear histone acetyltrans-
ferases, have been recently discovered to function as acetyl-lysine
binding domains. More recent structural studies of bromodo-
main/peptide ligand complexes have enriched our understanding
of differences in ligand selectivity of bromodomains. These new
findings demonstrate that bromodomain/acetyl-lysine recognition
can serve as a pivotal mechanism for regulating protein^protein
interactions in numerous cellular processes including chromatin
remodeling and transcriptional activation, and reinforce the
concept that functional diversity of a conserved protein modular
structure is achieved by evolutionary changes of amino acid
sequences in the ligand binding site. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The bromodomain, ¢rst reported in the Drosophila protein
brahma (hence the name) [1,2], represents an extensive family
of evolutionarily conserved protein modules found in many
chromatin-associated proteins and in nearly all known nuclear
histone acetyltransferases (HATs) [3]. While it has been long
suggested from yeast genetic studies that bromodomains play
an important role in chromatin remodeling [4^7], their speci¢c
biological functions only began to emerge after the recent
discovery that bromodomains function as acetyl-lysine bind-
ing domains [8^11]. This new ¢nding suggests a novel mech-
anism for regulating protein^protein interactions via lysine
acetylation, which has broad implications for the mechanisms
underlying a wide variety of cellular events, including chro-
matin remodeling and transcriptional activation [12^14]. Such
a mechanism supports the hypothesis that bromodomains can
contribute to highly speci¢c histone acetylation by tethering
transcriptional HATs to speci¢c chromosomal sites [4,15,16],
and to the assembly and activity of multi-protein complexes of
chromatin remodeling such as SAGA and NuA4 [17,18].
Moreover, bromodomain/acetyl-lysine recognition may also
help understand the underlying molecular mechanisms for a
wide range of phenotypes linked to bromodomain deletion.
For example, it has been shown that the bromodomain mod-
ule is indispensable for the function of GCN5 in yeast [19,20].
Deletion of a bromodomain in human HBRM, a protein in
the SWI/SNF remodeling complex, causes both decreased
stability and loss of nuclear localization [21,22]. Bromodo-
mains of Bdf1, a Saccharomyces cerevisiae protein, are re-
quired for sporulation and normal mitotic growth [23]. Fi-
nally, bromodomain deletion in Sth1, Rsc1 and Rsc2, three
members of the nucleosome remodeling complex RSC (re-
modeling the structure of chromatin), can cause a conditional
lethal phenotype (in Sth1) [24] or a strong phenotypic inhibi-
tion on cell growth (in Rsc1 and Rsc2) [25]. It is important to
note that the phenotypic e¡ect observed in Rsc1 and Rsc2
results from deletion of only the second but not the ¢rst
bromodomain, suggesting that these two bromodomains serve
distinct functions through interactions with di¡erent biologi-
cal ligands [25]. In this minireview, we focus on the recent
studies on ligand speci¢city of bromodomains.
2. The bromodomain structure
The three-dimensional structure of a prototypical bromo-
domain from the transcriptional co-activator p300/CBP-asso-
ciated factor (P/CAF) determined by using nuclear magnetic
resonance (NMR) spectroscopy showed that the bromodo-
main adopts an atypical left-handed four-helix bundle (helices
KZ, KA, KB and KC) (Fig. 1A) [8]. A long intervening loop
between helices KZ and KA (termed the ZA loop) is packed
against the loop connecting helices B and C (named the BC
loop) to form a surface-accessible hydrophobic pocket, which
is located at one end of the four-helix bundle, opposite the
amino and carboxy termini of the protein. Mutagenesis stud-
ies suggest that tertiary contacts amongst the hydrophobic
and aromatic residues between the two inter-helical loops con-
tribute directly to the structural stability of the protein [8].
This unique structural fold is highly conserved in the bro-
modomain family, as supported by several more recently de-
termined structures of bromodomains from human GCN5
[11] and S. cerevisiae GCN5p [10] as well as the double bro-
modomain module of human TAFII250 [9]. The structural
similarity amongst these bromodomains is very high for the
four helices with pairwise root-mean-square deviations of 0.7^
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1.8 Aî for the backbone CK atoms. The majority of structural
deviations are localized in the loop regions, particularly in the
ZA and BC loops. This observation is in an agreement with
the relatively high sequence variations in these loops (Fig. 2)
[3]. The modular structure supports the notion that bromodo-
mains act as a functional unit for protein interactions, and
multiple bromodomain modules can be placed sequentially in
a protein to serve similar or distinct functions [3,8].
3. Bromodomain as an acetyl-lysine binding domain
The discovery of acetyl-lysine recognition by bromodo-
mains is attributed to the unique ability of NMR spectroscopy
to measure changes of local chemical environment and/or
conformation of a protein induced upon binding to a ligand.
Weak but highly speci¢c interactions between a protein and a
ligand (with a dissociation constant KD in the WM^mM range)
can thus be detected with NMR. NMR titrations of the
P/CAF bromodomain revealed that the protein can bind to
lysine-acetylated peptides derived from major acetylation sites
on histones H3 or H4 in a highly speci¢c manner, and the
interaction is dependent upon acetylation of lysine [8]. This
observation was con¢rmed subsequently by the NMR study
of the human GCN5 bromodomain binding to lysine-acety-
Fig. 1. Di¡erences in ligand selectivity of bromodomains. A: The NMR solution structure of the P/CAF bromodomain (blue) in complex with
an lysine-acetylated peptide (green) derived from HIV-1 Tat at K50 (SYGR-AcK-KRRQR). B: The crystal structure of the scGCN5p bromo-
domain (red) in complex with a histone H4 peptide (green) containing K16 (A-AcK-RHRKILRNSIQGI). C: Stereoview of the scGCN5 bro-
modomain structure showing interactions of the protein (red) and the H4 peptide (green) residues in the ligand binding sites. D: Stereoview of
the P/CAF bromodomain structure showing interactions of the protein (blue) and the Tat peptide (green) residues in the ligand binding sites.
The protein residues are numbered according to the sequences, and the peptide residues are annotated according to their positions with respect
to the acetyl-lysine.
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lated histone H4 peptides [11]. The NMR structural analysis
of the P/CAF bromodomain in complex with acetyl-hista-
mine, a chemical analog of acetyl-lysine, showed that the ace-
tyl-lysine binding site is indeed localized to the hydrophobic
cavity between the ZA and BC loops [8]. The intermolecular
interactions are largely hydrophobic in nature, with the meth-
yl and methylene groups of acetyl-histamine making extensive
contacts with the side chains of V752, A757, Y760, Y802,
N803 and Y809, which are highly conserved throughout the
large family of bromodomains (Fig. 2) [8].
A crystal structure of scGCN5p bromodomain solved in
complex with an acetylated peptide derived from histone H4
at K16 (A-AcK-RHRKILRNSIQGI, where AcK is an NO-
acetyl lysine) reveals the atomic details of the acetyl-lysine
recognition (Fig. 1B) [10]. In addition to binding to the con-
served hydrophobic and aromatic residues seen in the P/CAF
bromodomain, the acetyl-lysine forms a speci¢c hydrogen
bond between the oxygen of the acetyl carbonyl group and
the side chain amide nitrogen of an absolutely conserved as-
paragine, N407 (corresponding to N803 in P/CAF) (Fig. 1C).
A network of water-mediated hydrogen bonds with protein
backbone carbonyl groups at the base of the cleft also con-
tributes to acetyl-lysine binding. Site-directed mutagenesis
con¢rmed the critical role of these amino acid residues in
binding to acetyl-lysine, suggesting that acetyl-lysine recogni-
tion is a general feature of bromodomains [8]. While the ma-
jor binding determinant in the scGCN5p bromodomain^H4
peptide complex is the acetylated lysine itself, the protein also
has a limited number of contacts with residues at (AcK+2)
and (AcK+3) in the H4 peptide. Speci¢cally, binding of the
aromatic ring of histidine at (AcK+2) interacts directly with
aromatic side chains of Y406 and F367, which are conserved
in the bromodomain family (Fig. 1C).
4. Di¡erences of ligand selectivity
The understanding of ligand selectivity of bromodomains is
greatly enhanced by the recent structural analysis of a highly
selective association between the P/CAF bromodomain and a
lysine-acetylated trans-activator protein Tat of human immu-
node¢ciency virus type 1 (HIV-1) [26]. Tat stimulates tran-
scriptional activation of the integrated HIV-1 genome and
promotes viral replication in infected cells [27^31]. Tat trans-
activation activity is dependent on acetylation at K50 by the
nuclear histone acetyltransferase p300/CBP and consequent
association with P/CAF via a bromodomain interaction [32^
34]. This bromodomain-mediated interaction results in the
release of lysine-acetylated Tat from TAR RNA association,
leading to Tat-mediated HIV-1 transcriptional activation [35^
37]. Deletion of P/CAF C-terminal region comprising the bro-
modomain potently abrogated Tat transactivation of inte-
grated, but not unintegrated HIV-1 LTR [35].
The new NMR structure of the P/CAF bromodomain in
complex with an acetylated Tat K50 peptide (SYGR-AcK-
KRRQR) showed that in addition to the acetyl-lysine, resi-
dues £anking both sides of the acetyl-lysine are important for
the complex formation (Fig. 1D). Y(AcK33) forms extensive
contacts with Y802 and V763, whereas R(AcK+3) and
Q(AcK+4) directly interact with E756. These speci¢c interac-
tions, con¢rmed by site-directed mutagenesis, confer a highly
selective association between the P/CAF bromodomain and
Tat [26]. The extensive ligand interactions explain why the
Fig. 2. Structure-based sequence alignment of a selected number of bromodomains. The sequences were aligned based on the experimentally de-
termined structures of ¢ve bromodomains, highlighted in orange. Note that in the P/CAF bromodomain a short helix in the ZA loop compris-
ing the YYEVI sequence (boxed by dashed lines) was only observed in the free but not in the peptide-bound form. The predicted secondary
structures in the other bromodomains are shaded in green. Bromodomains are grouped on the basis of the predicted structural similarities. Res-
idue numbers of the P/CAF bromodomain are indicated above its sequence. Absolutely (purple) or highly (blue) conserved residues are high-
lighted. In P/CAF, the residues directly interacting with the Tat peptide are shown in a larger font size, and residues essential for the acetyl-ly-
sine binding, as supported by mutagenesis, are underlined. P/CAF residues important for ligand speci¢city via interactions with the residues
£anking AcK in the Tat peptide are highlighted by red asterisks. In scGCN5, protein residues contacting the acetyl-lysine in the H4 peptide
are underlined, and residues contacting other parts of the peptide are indicated by red dots.
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P/CAF bromodomain binds to the Tat AcK50 peptide with a
binding a⁄nity (KDV10 WM) about 30-fold higher than that
for a histone H4 AcK16 peptide (KDV300 WM) [26]. The
di¡erences in ligand selectivity further explain the striking
di¡erences in both location and orientation of the bound pep-
tides in the P/CAF and scGCN5 bromodomains ^ the back-
bones of the Tat and H4 peptides lie in parallel in the two
corresponding structures but are oriented nearly opposite to
each other (Fig. 1C and D). Despite these di¡erences, it is
interesting to note that scGCN5p binding of H4 H(AcK+2)
is reminiscent of P/CAF bromodomain recognition of Tat
Y(AcK33) via residues Y802 and V763, which are equivalent
to residues Y406 and F367 in scGCN5p. Because of this sim-
ilar mode of molecular interaction, the two aromatic residues,
which are located in very di¡erent positions in the Tat and H4
peptides with respect to the acetyl-lysine, are found surpris-
ingly to be in a nearly identical position in the corresponding
bromodomain structures (Fig. 1C and D). High conservation
of these residues in bromodomains suggests that selection of
an aromatic or hydrophobic residue neighboring the acetyl-
lysine is possibly a common mechanism in the bromodomain
family (Fig. 2).
5. Perspective
Since bromodomain residues important for acetyl-lysine
recognition are largely conserved, binding of lysine-acetylated
proteins is likely a general biochemical function for bromodo-
mains. However, di¡erences in ligand selectivity may be at-
tributed to a few but important di¡erences in bromodomain
sequences (Fig. 2), which include (i) variations in the ZA
loops, which have relatively low sequence conservation and
amino acid deletion or insertion in di¡erent bromodomains;
and (ii) di¡erences in bromodomain residues that directly in-
teract with residues surrounding acetyl-lysine in a target pro-
tein. For instance, E756 in the bromodomain of P/CAF is
unique and only present in a small subset of bromodomains
from proteins including GCN5. An analogous residue in the
bromodomain of CBP or p300 is a leucine residue followed by
a two amino acid insertion that is also present in a small
subfamily of bromodomains (Fig. 2). Moreover, a short helix
corresponding to the AWPFM sequence in the ZA loop of P/
CAF (residues 745^749) is likely to be completely missing in
the TIF1L bromodomain due to an amino acid deletion. E756
of P/CAF is substituted with a two-residue AT motif in the
TIF1L sequence. These di¡erences in the ZA loop may explain
why the CBP and TIF1L bromodomains did not interact with
Tat AcK50 peptide [26].
In summary, the recent structural studies of bromodomains
demonstrate that like Src homology 2 (SH2) and phosphoty-
rosine binding (PTB) domains [38^41], which speci¢cally rec-
ognize tyrosine-phosphorylated proteins in signal transduction
[42,43], bromodomains can also bind with high selectivity to
lysine-acetylated proteins through speci¢c interactions with
amino acid residues £anking the acetyl-lysine [10,26]. This
new knowledge of ligand speci¢city will undoubtedly facilitate
our understanding of molecular mechanisms underlying spe-
ci¢c biological functions of bromodomains in cellular process-
es including chromatin remodeling and transcriptional activa-
tion. These structural studies further emphasize the concept
that functional diversity of a conserved protein modular struc-
ture is achieved by evolutionary changes of amino acid se-
quences in the ligand binding site. Tracking such an evolu-
tionary trail on the functional divergence of bromodomains
(particularly involving the ZA loop) will require detailed
knowledge of protein structure^function relationships, which
can be only acquired from three-dimensional structures of
new bromodomain/biological ligand complexes.
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